首页> Oncotarget> Cripto-1 as a novel therapeutic target for triple negative breast cancer.

Cripto-1 as a novel therapeutic target for triple negative breast cancer.

导出 OA

翻译打印收藏纠错

第一作者： Nadia P,Castro

第一单位： Tumor Growth Factor Section, Mouse Cancer Genetics Program, National Cancer Institute, Frederick, MD, USA.

作者： Nadia P,Castro ^[1] ; Natalie D,Fedorova-Abrams ^[2] ; Anand S,Merchant ^[2] ; Maria Cristina,Rangel ^[1] ; Tadahiro,Nagaoka ^[1] ; Hideaki,Karasawa ^[1] ; Malgorzata,Klauzinska ^[1] ; Stephen M,Hewitt ^[3] ; Kajal,Biswas ^[4] ; Shyam K,Sharan ^[4] ; David S,Salomon ^[1]

作者单位： Tumor Growth Factor Section, Mouse Cancer Genetics Program, National Cancer Institute, Frederick, MD, USA. ^[1] CCRIFX Bioinformatics Core, National Cancer Institute, Bethesda, MD, USA. ^[2] Laboratory of Pathology, Center for Cancer Research, National Cancer Institute, Bethesda, MD, USA. ^[3] Genetics of Cancer Susceptibility Section, Mouse Cancer Genetics Program, National Cancer Institute, Frederick, MD, USA. ^[4]

关键词 Cripto-1 Notch4 epithelial-mesenchymal plasticity mouse model triple-negative breast cancer